All In Biotech

Drug Trial Radar · NCT05970575

Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury

Open Label Phase IIa Study Evaluating the Safety and Efficacy of NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

4

Actual

Start

Dec 21, 2023

Primary completion

Jul 21, 2025

Study completion Jul 21, 2025

Sponsor

Lead sponsor
Neurological Associates of West Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BioVie Inc.
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Traumatic Brain Injury and inflammatory and metabolic parameters.

Conditions

  • Traumatic Brain Injury

Interventions

  • NE3107Drug

    Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (6 months)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as Assessed by Quantification of Adverse EventsTime frame: up to 6 months
  2. Pittsburgh Sleep Quality Index (PSQI)Time frame: Baseline, 3 months, 6 months
  3. Multidimensional Fatigue Inventory (MFI)Time frame: Baseline, 3 Months, 6 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Regenesis Project

    Santa Monica, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.